These findings identify AA as a novel inhibitor of the RANKL-MAPK-NFATc1 axis, providing a mechanistic foundation for its therapeutic development in osteoporosis and other osteolytic diseases. The gene discussed is TNFSF11; the disease is osteoporosis.